Yale University | Good News For Humankind

Nearly 9 in 10 Americans now think using psilocybin is ‘morally positive,’ in dramatic shift in public opinion

By Peter Schulte / March 18, 2024

Researchers—representing institutions such as the universities of Oxford, Yale, Johns Hopkins, and Grenada—surveyed 795 people on the issue, asking about supervised use specifically for treatment and for well-being enhancement. Participants, the report says, “rated the individual’s decision as morally positive in both contexts.” The study is of note because although psilocybin “has shown promise both as a treatment for psychiatric conditions and as a means of improving well-being in healthy individuals,” authors wrote.

Cancer vaccine for dogs almost doubles survival rates in clinical trial

By Peter Schulte / March 5, 2024

Scientists at Yale University adapted existing human cancer treatments to find a new version that could benefit both humans and dogs. After conducting multiple clinical trials involving over 300 dogs over the past eight years, the researchers say that their canine cancer vaccine has almost doubled the 12-month survival rate for dogs with some types of cancer.

Yale, University of New Haven partnership celebrates first degrees awarded to inmates

By Peter Schulte / June 9, 2023

In 2021, Yale partnered with UNH to give student-inmates a path to two and four year college degrees. The program is now part of a consortium that includes 15 schools and prison systems across the country.

New treatment helps alopecia patients regrow their hair

By Peter Schulte / April 14, 2022

A new Yale study shows that one in three patients with a severe skin disease were able to regrow hair after being treated with a common arthritis drug.

Electronic waste on the decline in the United States

By Peter Schulte / December 11, 2020

A new study led by a researcher at the Yale School of the Environment has found that the total mass of electronic waste generated by Americans has been declining since 2015.

First of-its-kind study suggests psilocybin can help treat migraines

By Peter Schulte / December 3, 2020

A first-of-its-kind exploratory study, led by researchers from Yale School of Medicine, has found a single dose of the psychedelic psilocybin can reduce migraine frequency by 50 percent for a least two weeks.

Louis S. Goodman and Alfred Gilman of Yale School of Medicine run first human trial of cancer chemotherapy

By Peter Schulte / August 27, 1942

In collaboration with a thoracic surgeon, Gustaf Lindskog, they injected the chemical mustine into a patient with non-Hodgkin’s lymphoma. The patient, a Polish immigrant to Connecticut known in literature only as JD, received his first injections on August 27, 1942 at 10 a.m. The doctors observed a dramatic reduction in the patient’s tumor masses.